ReviewCurrent oncology reports2021
Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors.
Review in Current oncology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of apatinib monotherapy for patients with advanced breast cancer: a systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Anti-PD-L1 envafolimab combined with anti-VEGF suvemcitug in pretreated solid tumors and hepatocellular carcinoma: an open-label phase II study with safety run-in stage.Investigational new drugs · 2025Trial
- Recent progress and therapeutic strategies in the treatment of cervical neuroendocrine neoplasms (Review).International journal of molecular medicine · 2026Review
- PRMT6 acts as a pro-angiogenic factor in colorectal cancer.Cell death discovery · 2026Article
- Anlotinib inhibits esophageal cancer malignancy by ameliorating the immune microenvironment.Discover oncology · 2026Article
- Rationale of using immune checkpoint inhibitors (ICIs) and anti-angiogenic agents in cancer treatment from a molecular perspective.Clinical and experimental medicine · 2025Review
- Pan-cancer analysis reveals the prognostic and immunomodulatory potential of super-enhancer-induced ANGPT2 and experimental validation in colorectal cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025Article
- Narrative review on efficacy and safety of anti-angiogenesis in combination with immunotherapy in the treatment of breast cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024Review
- Direct antitumor activity of bevacizumab: an overlooked mechanism?Frontiers in pharmacology · 2024Article
- A novel angiogenesis-related scoring model predicts prognosis risk and treatment responsiveness in diffuse large B-cell lymphoma.Clinical and experimental medicine · 2023Article
- Immune suppressive microenvironment in liver metastases contributes to organ-specific response of immunotherapy in advanced non-small cell lung cancer.Journal for immunotherapy of cancer · 2023Observational
- Article
- Drugging Hijacked Kinase Pathways in Pediatric Oncology: Opportunities and Current Scenario.Pharmaceutics · 2023Review
- Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022.Frontiers in immunology · 2023Article
- Vascular normalization: reshaping the tumor microenvironment and augmenting antitumor immunity for ovarian cancer.Frontiers in immunology · 2023Review
- Role of Immune Cells and Receptors in Cancer Treatment: An Immunotherapeutic Approach.Vaccines · 2022Review
- Metastasis prevention: targeting causes and roots.Clinical & experimental metastasis · 2022Review
- Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Review
- Evolving cancer-niche interactions and therapeutic targets during bone metastasis.Nature reviews. Cancer · 2022Review
- Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications.Frontiers in oncology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewBoth anti-angiogenesis and immunotherapy are well-established therapeutic options in solid tumors. Here, we review the rationale as well as clinical evidence of combining these two approaches. RECENT
findingsThere is strong rationale and substantial preclinical and clinical evidence that anti-angiogenesis plays a pivotal role in overcoming immunotherapy resistance. The combination of an anti-angiogenic agent and a checkpoint inhibitor offers a more robust treatment option in many clinical trials in a wide variety of solid tumor types. Combination of anti-angiogenesis and immunotherapy has emerged as a standard of care in some tumor types and the indication is expected to expand to more tumor types in the years to come.
Indexed as
Identifiers
34269922What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.